T1	PrimaryOutcome 482 515	negative conversion of SARS-CoV-2
T2	PrimaryOutcome 573 593	clinical improvement
T4	TimeFrame 594 604	by 28 days
R2	MeasuredAt Arg1:T2 Arg2:T4	
T5	OutcomeDefinition 802 958	two consecutive reports of a negative result for SARS-CoV-2 at least 24 hours apart without a subsequent report of a positive result by the end of the study
R3	DefinedAs Arg1:T1 Arg2:T5	
T6	PrimaryOutcome 1120 1144	Negative conversion rate
A2	Modification T6 Original
A3	Modification T1 Modified
T3	SecondaryOutcome 1629 1663	Probability of negative conversion
T7	TimeFrame 1664 1690	at day 4, 7, 10, 14, or 21
R1	MeasuredAt Arg1:T3 Arg2:T7	
T8	SecondaryOutcome 1861 1875	adverse events
#1	AnnotatorNotes T8	prespecified
#2	AnnotatorNotes T3	not in the trial registration, but in protocol
T9	SecondaryOutcome 2231 2280	probabilities of alleviation of clinical symptoms
#3	AnnotatorNotes T9	not in the trial registration
T10	SecondaryOutcome 2282 2315	improvement of C reactive protein
#4	AnnotatorNotes T10	not in the trial registration
T11	SecondaryOutcome 2317 2347	erythrocyte sedimentation rate
#5	AnnotatorNotes T11	not in the trial registration
T12	SecondaryOutcome 2349 2373	tumour necrosis factor α
#6	AnnotatorNotes T12	not in the trial registration
T13	SecondaryOutcome 2375 2388	interleukin 6
#7	AnnotatorNotes T13	not in the trial registration
T14	SecondaryOutcome 2394 2425	absolute blood lymphocyte count
#8	AnnotatorNotes T14	not in the trial registration
T15	SecondaryOutcome 2427 2473	improvement of lung lesions on chest radiology
#9	AnnotatorNotes T15	not in the trial registration
T16	SecondaryOutcome 2475 2490	all cause death
#10	AnnotatorNotes T16	not in the trial registration
T17	SecondaryOutcome 2496 2557	disease progression in patients with mild to moderate disease
#11	AnnotatorNotes T17	not in the trial registration
T18	TimeFrame 2607 2636	from randomisation to 28 days
R4	MeasuredAt Arg1:T8 Arg2:T18	
R5	MeasuredAt Arg1:T9 Arg2:T18	
R6	MeasuredAt Arg1:T10 Arg2:T18	
R7	MeasuredAt Arg1:T11 Arg2:T18	
R8	MeasuredAt Arg1:T12 Arg2:T18	
R9	MeasuredAt Arg1:T13 Arg2:T18	
R10	MeasuredAt Arg1:T14 Arg2:T18	
R11	MeasuredAt Arg1:T15 Arg2:T18	
R12	MeasuredAt Arg1:T16 Arg2:T18	
R13	MeasuredAt Arg1:T17 Arg2:T18	
T19	SecondaryOutcome 3009 3041	alleviation of clinical symptoms
T20	TimeFrame 3042 3056	within 28 days
R14	MeasuredAt Arg1:T19 Arg2:T20	
T21	OutcomeDefinition 3189 3431	resolving from fever to an axillary temperature of 36.6°C or below, normalisation of SpO2 (>94% on room air), and disappearance of respiratory symptoms including nasal congestion, cough, sore throat, sputum production, and shortness of breath
R15	DefinedAs Arg1:T19 Arg2:T21	
T22	TimeFrame 516 526	by 28 days
R16	MeasuredAt Arg1:T1 Arg2:T22	
T23	TimeFrame 1145 1154	by Day 10
R17	MeasuredAt Arg1:T6 Arg2:T23	
T24	OutcomeDefinition 1876 2115	coded using the latest version of Medical Dictionary for Regulatory Activities coding dictionary, recorded in standard medical terminology and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events
R18	DefinedAs Arg1:T8 Arg2:T24	
T25	PrimaryOutcome 1528 1561	negative conversion of SARS-CoV-2
A4	Modification T25 Modified
T26	TimeFrame 1562 1572	by 28 days
R19	MeasuredAt Arg1:T25 Arg2:T26	
T27	PrimaryOutcome 21 91	Negative conversion of severe acute respiratory syndrome coronavirus 2
T28	TimeFrame 92 102	by 28 days
R20	MeasuredAt Arg1:T27 Arg2:T28	
A5	Modification T27 Modified
T29	OtherOutcome 160 174	Adverse events
